These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4403857)

  • 1. Activation of the antineoplastic drug isophosphamide by rat liver microsomes.
    Allen LM; Creaven PJ
    J Pharm Pharmacol; 1972 Jul; 24(7):585-6. PubMed ID: 4403857
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes.
    Allen LM; Creaven PJ
    Cancer Chemother Rep; 1972 Oct; 56(5):603-10. PubMed ID: 4405717
    [No Abstract]   [Full Text] [Related]  

  • 3. Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.
    Alarcon RA; Meienhofer J; Atherton E
    Cancer Res; 1972 Nov; 32(11):2519-23. PubMed ID: 5082597
    [No Abstract]   [Full Text] [Related]  

  • 4. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.
    Connors TA; Cox PJ; Farmer PB; Foster AB; Jarman M
    Biochem Pharmacol; 1974 Jan; 23(1):115-29. PubMed ID: 4811053
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.
    Takamizawa A; Matsumoto S; Iwata T; Tochino Y; Katagiri K
    J Med Chem; 1974 Nov; 17(11):1237-9. PubMed ID: 4416021
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical pharmacology of isophosphamide.
    Creaven PJ; Allen LM; Alford DA; Cohen MH
    Clin Pharmacol Ther; 1974 Jul; 16(1):77-86. PubMed ID: 4602057
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.
    Hill DL; Laster WR; Kirk MC; el-Dareer S; Struck RF
    Cancer Res; 1973 May; 33(5):1016-22. PubMed ID: 4703116
    [No Abstract]   [Full Text] [Related]  

  • 8. Interaction of mechlorethamine and isophosphamide with bovine serum albumin and rat liver microsomes.
    Allen LM; Creaven PJ
    J Pharm Sci; 1973 May; 62(5):854-6. PubMed ID: 4705708
    [No Abstract]   [Full Text] [Related]  

  • 9. Teratogenicity and neonatal toxicity of ifosfamide in mice.
    Bus JS; Gibson JE; Reinke DA
    Proc Soc Exp Biol Med; 1973 Sep; 143(4):965-70. PubMed ID: 4743716
    [No Abstract]   [Full Text] [Related]  

  • 10. [Activation of ifosfamide in man and animal].
    Brock N; Hoefer-Janker H; Hohorst HJ; Scheef W; Schneider B; Wolf HC
    Arzneimittelforschung; 1973 Jan; 23(1):1-14. PubMed ID: 4353374
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal dysfunction after treatment with isophosphamide (NSC-109724).
    DeFronzo RA; Abeloff M; Braine H; Humphrey RL; Davis PJ
    Cancer Chemother Rep; 1974; 58(3):375-82. PubMed ID: 4842666
    [No Abstract]   [Full Text] [Related]  

  • 12. Gas chromatographic method for the determination of plasma isophosphamide (NSC-109724).
    Allen LM; Creaven PJ
    Cancer Chemother Rep; 1972 Dec; 56(6):721-3. PubMed ID: 4660630
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.
    Pantarotto C; Bossi A; Belvedere G; Martini A; Donelli MG; Frigerio A
    J Pharm Sci; 1974 Oct; 63(10):1554-8. PubMed ID: 4436788
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver.
    Burke MD; Thompson S; Weaver RJ; Wolf CR; Mayer RT
    Biochem Pharmacol; 1994 Aug; 48(5):923-36. PubMed ID: 8093105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of ifosfamide in the treatment of malignant neoplasms].
    Czownicki Z; Utracka B; Till A; Styrna M
    Nowotwory; 1973; 23(3):285-90. PubMed ID: 4757587
    [No Abstract]   [Full Text] [Related]  

  • 16. The relationship between the metabolism of 2,4-dichloro-6-phenylphenoxyethylamine (DPEA) and related compounds and their activities as microsomal mono-oxygenase inhibitors.
    Parli CJ; Lee NW; McMahon RE
    Drug Metab Dispos; 1973; 1(4):628-33. PubMed ID: 4149636
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.
    Ahmann DL; Bisel HF; Hahn RG
    Cancer Chemother Rep; 1974; 58(6):861-5. PubMed ID: 4615785
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
    Bremner DN; McCormick JS; Thomson JW
    Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
    [No Abstract]   [Full Text] [Related]  

  • 19. [Relation between the 7-ethoxyresorufin-O-deethylase activity of the liver microsomal monooxygenase system and the level of methylcholanthrene-induced form of cytochrome P-450].
    Grishanova AIu; Peregoedova EL; Mishin VM; Liakhovich VV
    Biokhimiia; 1988 Jun; 53(6):956-9. PubMed ID: 3179354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal conditions for the hydrolysis of seclazone by rat hepatic microsomes.
    Edelson J; Schuster EB; Douglas JF
    Arch Int Pharmacodyn Ther; 1974 Sep; 211(1):99-106. PubMed ID: 4218724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.